This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Feb;12(2):112-3.

doi: 10.1016/S1470-2045(11)70005-5. Epub 2011 Jan 20.

Adjuvant interferon: recommit or move on?

Ragini Kudchadkar¹, Vernon Sondak

Affiliations

PMID: 21256808
DOI: 10.1016/S1470-2045(11)70005-5

Comment

Adjuvant interferon: recommit or move on?

Ragini Kudchadkar et al. Lancet Oncol. 2011 Feb.

. 2011 Feb;12(2):112-3.

doi: 10.1016/S1470-2045(11)70005-5. Epub 2011 Jan 20.

Authors

Ragini Kudchadkar¹, Vernon Sondak

Affiliation

¹ H Lee Moffitt Cancer Center, Tampa, FL 33612, USA.

PMID: 21256808
DOI: 10.1016/S1470-2045(11)70005-5

No abstract available

PubMed Disclaimer

Comment on

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group. Hansson J, et al. Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20. Lancet Oncol. 2011. PMID: 21256809 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information